These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2539206)

  • 1. Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study.
    Pickar D; Bunney WE; Douillet P; Sethi BB; Sharma M; Vartanian ME; Lideman RP; Naber D; Leibl K; Yamashita I
    Biol Psychiatry; 1989 Feb; 25(4):440-8. PubMed ID: 2539206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study.
    Pickar D; Vartanian F; Bunney WE; Maier HP; Gastpar MT; Prakash R; Sethi BB; Lideman R; Belyaev BS; Tsutsulkovskaja MV; Jungkunz G; Nedopil N; Verhoeven W; van Praag H
    Arch Gen Psychiatry; 1982 Mar; 39(3):313-9. PubMed ID: 6121545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated naloxone administration in schizophrenia.
    Verhoeven WM; van Praag HM; van Ree JM
    Psychiatry Res; 1984 Aug; 12(4):297-312. PubMed ID: 6594713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone-induced reduction of schizophrenic symptoms.
    Jørgensen HA; Cappelen C
    Acta Psychiatr Scand; 1982 May; 65(5):370-4. PubMed ID: 6126068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
    Kurland AA; McCabe OL; Hanlon TE; Sullivan D
    Am J Psychiatry; 1977 Dec; 134(12):1408-10. PubMed ID: 335903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of naloxone in chronic schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Am J Psychiatry; 1981 Jul; 138(7):913-8. PubMed ID: 6266259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist.
    Naber D; Münch U; Wissmann J; Grosse R; Ritt R; Welter D
    Acta Psychiatr Scand; 1983 Apr; 67(4):265-71. PubMed ID: 6305111
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients.
    Pickar D; Davis GC; Schulz SC; Extein I; Wagner R; Naber D; Gold PW; van Kammen DP; Goodwin FK; Wyatt RJ; Li CH; Bunney WE
    Am J Psychiatry; 1981 Feb; 138(2):160-6. PubMed ID: 6257125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
    Kleinman JE; Weinberger DR; Rogol A; Shiling DJ; Mendelson WB; Davis GC; Bunney WE; Wyatt RJ
    Psychiatry Res; 1982 Aug; 7(1):1-7. PubMed ID: 6127744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose naloxone administration in chronic schizophrenia.
    Cohen MR; Pickar D; Cohen RM
    Biol Psychiatry; 1985 May; 20(5):573-5. PubMed ID: 3886025
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical studies on the role of endorphins in schizophrenia.
    Berger PA; Watson SJ; Akil H; Barchas JD
    Mod Probl Pharmacopsychiatry; 1981; 17():226-35. PubMed ID: 6276727
    [No Abstract]   [Full Text] [Related]  

  • 12. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients.
    Naber D; Leibl K
    Pharmacopsychiatria; 1983 Mar; 16(2):43-5. PubMed ID: 6346348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 14. Negative naloxone effects in schizophrenic patients.
    Janowsky DS; Segal DS; Abrams A; Bloom F; Guillemin R
    Psychopharmacology (Berl); 1977 Aug; 53(3):295-7. PubMed ID: 19807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects.
    Lehmann H; Nair NP; Kline NS
    Am J Psychiatry; 1979 Jun; 136(6):762-6. PubMed ID: 220889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous naloxone administration in schizophrenia and affective illness.
    Davis GC; Bunney WE; DeFraites EG; Kleinman JE; van Kammen DP; Post RM; Wyatt RJ
    Science; 1977 Jul; 197(4298):74-7. PubMed ID: 325650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-Endorphin and schizophrenia.
    Berger PA; Watson SJ; Akil H; Elliott GR; Rubin RT; Pfefferbaum A; Davis KL; Barchas JD; Li CH
    Arch Gen Psychiatry; 1980 Jun; 37(6):635-40. PubMed ID: 7387335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
    Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
    Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose naloxone acutely reduces eating in obese humans: behavioral and biochemical effects.
    Wolkowitz OM; Doran AR; Cohen MR; Cohen RM; Wise TN; Pickar D
    Biol Psychiatry; 1988 Aug; 24(4):483-7. PubMed ID: 2841988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.